Abstract

目的探讨SLAMF6在重型再生障碍性贫血(SAA)CD8+ T细胞中的表达情况及其与疾病免疫状态的相关性。方法选取2017年2月至2018年4月天津医科大学总医院血液科收治的初治SAA患者21例,以15例健康人外周血标本作为正常对照,应用流式细胞术(FCM)检测外周血CD8+ T细胞SLAMF6表达量,并与患者HGB、PLT、中性粒细胞绝对值、网织红细胞绝对值、骨髓造血功能(粒系百分比、红系百分比、淋系百分比、巨核细胞数)等临床指标及CD8+ T细胞功能分子穿孔素、颗粒酶B、IFN-γ表达量进行相关性分析。进一步采用anti-SLAMF6 Ab阻断其功能,FCM检测CD8+ T细胞穿孔素、颗粒酶B、IFN-γ分泌量。结果初治SAA患者CD8+ T细胞SLAMF6表达量明显低于正常对照,差异有统计学意义[(56.29±12.97)%对(80.96±7.36)%,t=−7.672,P<0.001];初治SAA患者CD8+ T细胞SLAMF6表达量与HGB、PLT、中性粒细胞绝对值、网织红细胞绝对值、骨髓粒系百分比、骨髓红系百分比均呈正相关(P<0.05),与CD8+ T细胞穿孔素、颗粒酶B、IFN-γ表达量均呈负相关(P<0.05);anti-SLAMF6 Ab阻断该信号分子后,初治SAA患者CD8+ T细胞anti-SLAMF6 Ab处理组穿孔素、颗粒酶B、IFN-γ表达量较未处理组明显增多,差异有统计学意义(P值均<0.05)。结论SLAMF6在SAA患者CD8+ T细胞中明显低表达,其可能作为负性免疫调节分子通过影响CD8+ T细胞功能分子的分泌参与SAA的发生机制。

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.